Aspira Women's Health
Ovarian Cancer Risk Assessment For Women with Pelvic Masses with OvaSuiteSM
Aspira Women's Health
OvaView: Monitor Ovarian Cancer Risk with OvaWatch®
Aspira Women's Health
OvaView: OvaWatch® vs. Ova1Plus®
Aspira Women's Health
Introducing "The OvaView"
Aspira Women's Health
OvaView: The Power of Ova1®
Aspira Women's Health
OvaView: The Power of OvaWatch®
Aspira Women's Health
A Protein Biomarker Test and Artificial Intelligence-Based Algorithm for Ovarian Endometriosis
Aspira Women's Health
CAGLA Investment Track: CFO Torsten Hombeck - NeauxCancer Conference 2024
Aspira Women's Health
New to The Street Interview with Aspira's, Nicole Sandford, Michelle Snider, and Lottie Wilder
Aspira Women's Health
Dr. Leo Twiggs, Director of Medical Affairs, Aspira Women's Health on The Bill Meyer Show
Aspira Women's Health
KOL Webinar: Assessing Ovarian Cancer Risk with OvaWatchSM. Feat. Dr. Leo Twiggs & Dr. Andrew Bokor
Aspira Women's Health
New to The Street Interview with Aspira CEO Nicole Sandford and Dr. Tamika Sea, MD, FACOG
Aspira Women's Health
New to The Street Interview with Nicole Sandford, CEO
Aspira Women's Health
Aspira CEO, Nicole Sandford fireside chat with Sally Yanchus of Water Tower Research, LLC.
Aspira Women's Health
Discussing Ovarian Cancer Risk Assessment on The Balancing Act: April 10, 2023
Aspira Women's Health
The Impact of Health Disparities in Ovarian Cancer Care
Aspira Women's Health
The Impact of Health Disparities in Ovarian Cancer Care
Aspira Women's Health
Ovarian Cancer Risk Assessments Utilizing Multivariate Index Assay
Aspira Women's Health
Ovarian Cancer Risk Assessments Utilizing Multivariate Index Assay
Aspira Women's Health
Dr Black Testimonial
Aspira Women's Health
Dr. Howard C. Mandel Testimonial
Aspira Women's Health
Affordable and Accessible for All – Ovarian Cancer Risk Assessment Test for women with pelvic masses
Aspira Women's Health
International Women's Day 2021